Skip to main content

Table 4 Longitudinal changes in annual pre-bronchodilator forced expiratory volume in 1 s (mL) between non-ACO COPD and ACO

From: Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort

 

Non-ACO COPD (n = 192)

ACO (n = 47)

P for interaction*

Crude, mL

−29.26 (−35.78, −22.75)

−13.87 (− 27.22, − 0.52)

0.042

Model 1, mL

− 29.17 (− 35.73, − 22.61)

−13.58 (− 27.01, − 0.14)

0.041

Model 2, mL

−29.19 (− 35.74–22.64)

−13.64 (− 27.07, − 0.22)

0.041

Model 3, mL

−29.16 (− 35.73, − 22.60)

−13.61 (− 27.06, − 0.17)

0.042

  1. Data are presented as mean (95% confidence interval)
  2. Model 1: Adjusted for baseline age, baseline body mass index and smoking status during the study period; Model 2: Further adjusted for at least 2 exacerbations per a year during study period; Model 3: Further adjusted for use of ICS/LABA or ICS during the study period
  3. Abbreviations: ACO asthma-chronic obstructive pulmonary disease overlap, COPD chronic obstructive lung disease, ICS inhaled corticosteroids, LABA long-acting β2-agonists
  4. *P value for homogeneity of annual change by group
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us